Stress, Alkohol, Zigaretten, Medikamente, Elektrosmog, radioaktive Belastungen und weitere belastende Faktoren gesellen sich dazu
Limitations include that the data came from 1 health system in the US, most patients were white, and it was unknown why patients were prescribed this medication, although 93% were diabetic
Although this is less common when Semaglutide GLP-1 is used alone as a monotherapy, the associated risk escalates in conjunction with other diabetic drugs, particularly insulin and sulfonylureas
This is the minimum timeframe established by clinical trial protocols for safe dose escalation
To help ease some of the side effects from GLP-1s, doctors typically start at a lower dose and increase gradually to help the body adjust to the medicine as its increased
Exclusion criteria in studies typically include Wilson's disease, copper allergy, and pregnancy due to insufficient data in those populations